GLP-1tirzepatidesemaglutidetype 2 diabetescardiovascular outcomes

TriNetX analysis links tirzepatide to fewer cardiovascular events than semaglutide

In 271,685 matched pairs with type 2 diabetes, all-cause mortality was 0.6% with tirzepatide versus 0.9% with semaglutide.

By Maren Holt · Senior Reporter, GLP-1

Oct 4 20:00 ETSource: Journal of diabetes and metabolic disorders

The wire

01Using TriNetX real-world records from May 2022 to August 2026, researchers found a composite of myocardial infarction, stroke and acute heart failure in 4.6% of tirzepatide users versus 5.5% of semaglutide users (HR 0.9).
02The comparison addresses a gap for prescribers choosing between the two incretins, since tirzepatide has only been shown non-inferior to dulaglutide on cardiovascular risk.
03This is propensity-matched observational data, not a randomized head-to-head trial, so residual confounding by indication, adherence and dose remains possible.

From the source

Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes
Journal of diabetes and metabolic disorders · 2026 Dec · Al-Nusair M, Khurana S, Eysha M et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42840232/